Home > Boards > US OTC > Miscellaneous >

Enzolytics Inc. (ENZC)

ENZC RSS Feed
Add ENZC Price Alert      Hide Sticky   Hide Intro
Moderator: Welcome2Pinkyland, ilovestocks85, MIKEY501, BigJuan, moolamoola, Q7
Search This Board: 
Last Post: 9/27/2020 9:40:05 PM - Followers: 401 - Board type: Free - Posts Today: 75

 
https://enzolytics.com/home

image8

Patent US-7479538

Enzolytics has a License Agreement for US Patent 7479538. The claim is Irreversibly-inactivated Pepsinogen Fragments for Modulating Immune Function. 

 

Independent Valuation Report Pre Clinical Studies

HIV & AIDS INFO

Global HIV & AIDS statistics — 2019 fact sheet

Global HIV statistics

 

  • 24.5 million [21.6 million–25.5 million] people were accessing antiretroviral therapy (end ofJune 2019).
    37.9 million [32.7 million–44.0 million] people globally were living with HIV (end 2018).
    1.7 million [1.4 million–2.3 million] people became newly infected with HIV (end 2018).
    770 000 [570 000–1.1 million] people died from AIDS-related illnesses (end 2018).
    74.9 million [58.3 million–98.1 million] people have become infected with HIV since the start of the epidemic (end 2018).
    32.0 million [23.6 million–43.8 million] people have died from AIDS-related illnesses since the start of the epidemic (end 2018).

 

People living with HIV

 

  • In 2018, there were 37.9 million [32.7 million–44.0 million] people living with HIV.
    • 36.2 million [31.3 million–42.0 million] adults.
      1.7 million [1.3 million–2.2 million] children (<15 years).

    79% [67–92%] of all people living with HIV knew their HIV status.
    About 8.1 million people did not know that they were living with HIV.

 

People living with HIV accessing antiretroviral therapy

 

  • As of end of June 2019, 24.5 million [21.6 million–25.5 million] people were accessingantiretroviral therapy.
    In 2018, 23.3 million [20.5 million–24.3 million] people living with HIV were accessing antiretroviral therapy, up from 7.7 million [6.8 million–8.0 million] in 2010.
    In 2018, 62% [47–74%] of all people living with HIV were accessing treatment.
    • 62% [47–75%] of adults aged 15 years and older living with HIV had access to treatment, as did 54% [37–73%] of children aged 0–14 years.
      68% [52-82%] of female adults aged 15 years and older had access to treatment however, just 55% [41-68%] of male adults aged 15 years and older had access.

    82% [62– >95%] of pregnant women living with HIV had access to antiretroviral medicines to prevent transmission of HIV to their child in 2018.

 

New HIV infections

 

  • New HIV infections have been reduced by 40% since the peak in 1997.
    • In 2018, around 1.7 million [1.4 million–2.3 million] were newly infected with HIV, compared to 2.9 million [2.3 million–3.8 million] in 1997.

    Since 2010, new HIV infections have declined by an estimated 16%, from 2.1 million [1.6 million–2.7 million] to 1.7 million [1.4 million–2.3 million] in 2018.
    • Since 2010, new HIV infections among children have declined by 41%, from 280 000 [190 000–430 000] in 2010 to 160 000 [110 000–260 000] in 2018.

 

AIDS-related deaths

 

  • AIDS-related deaths have been reduced by more than 56% since the peak in 2004.
    • In 2018, around 770 000 [570 000–1.1 million] people died from AIDS-related illnesses worldwide, compared to 1.7 million [1.3 million–2.4 million] in 2004 and 1.2 million [860 000–1.6 million] in 2010.

    AIDS-related mortality has declined by 33% since 2010.

 

90–90–90

 

  • In 2018, 79% [67–92%] of people living with HIV knew their status.
    Among people who knew their status, 78% [69–82%] were accessing treatment.
    And among people accessing treatment, 86% [72–92%] were virally suppressed.
    Of all people living with HIV, 79% [67-92%] knew their status, 62% [47-74%] were accessing treatment and 53% [43-63%] were virally suppressed in 2018.

 

Women

 

  • Every week, around 6000 young women aged 15–24 years become infected with HIV.
    • In sub-Saharan Africa, four in five new infections among adolescents aged 15–19 years are in girls. Young women aged 15–24 years are twice as likely to be living with HIV than men.

    More than one third (35%) of women around the world have experienced physical and/or sexual violence at some time in their lives.
    • In some regions, women who have experienced physical or sexual intimate partner violence are 1.5 times more likely to acquire HIV than women who have not experienced such violence.

 

Key populations

 

  • Key populations and their sexual partners account for:
    • 54% of new HIV infections globally.
      More than 95% of new HIV infections in Eastern Europe and Central Asia.
      95% of new HIV infections in Middle East and North Africa.
      88% of new HIV infections in Western and central Europe and North America.
      78% of new HIV infections in Asia and the Pacific.
      65% of new HIV infections in Latin America.
      64% of new HIV infections in Western and central Africa.
      47% of new HIV infections in the Caribbean.
      25% of new HIV infections in eastern and southern Africa.

    The risk of acquiring HIV is:
    • 22 times higher among men who have sex with men.
      22 times higher among people who inject drugs.
      21 times higher for sex workers.
      12 times higher for transgender people.

 

HIV/tuberculosis (TB)

 

  • TB remains the leading cause of death among people living with HIV, accounting for around one in three AIDS-related deaths.
    In 2017, an estimated 10.0 million [9.0-11.1million] people developed TB disease, approximately 9% were living with HIV.
    • People living with HIV with no TB symptoms need TB preventative therapy, which lessens the risk of developing TB and reduces TB/HIV death rates by around 40%.

    It is estimated that 49% of people living with HIV and tuberculosis are unaware of their coinfection and are therefore not receiving care.

 

Investments

 

  • At the end of 2018, US$ 19.0 billion (constant 2016 dollars) was available for the AIDS response in low- and middle-income countries, almost 1 billion less than in 2017.
    • Around 56% of the total resources for HIV in low- and middle-income countries in 2018 were from domestic sources.

    UNAIDS estimates that US$ 26.2 billion (constant 2016 dollars) will be required for the AIDS response in 2020.

 

Download the full version to view regional statistics, global and regional data

 

Source: 

https://www.unaids.org/en/resources/fact-sheet

image25

SITE CONTENT

Number of deaths due to HIV/AIDS

Situation and trends

 

Expanded access to antiretroviral therapy (ART) and a declining incidence of HIV infections have led to a steep fall globally in the number of adults and children dying from HIV-related causes. The estimated 770 000 [570 000−1 100 000] people dying from HIV globally in 2018 were 56% fewer than in 2004 (the peak) and 33% fewer than in 2010 in spite of a period of substantial population growth in many high burden countries.

 

Nevertheless, there is no room for complacency. Countries need to live up to their commitment to end the AIDS epidemic as a public health threat by 2030 -- a target included in the 2030 Agenda for Sustainable Development adopted by the United Nations General Assembly in September 2015. The immediate challenge is to reach the Fast-Track targets for 2020, as HIV-related deaths are still unacceptably high.

 

The 2020 targets include reducing the number of people dying from HIV-related causes to fewer than 500 000. Based on current estimates, this provides an opportunity to prevent almost 300 000 deaths per year.

 

The drop in HIV-related mortality is especially evident in the regions with the greatest burden of HIV infection, including the WHO African Region, home to over 61% of people dying from HIV-related causes in 2018. An estimated 470 000 [340 000−630 000] people died in the African Region from HIV-related causes in 2018, which indicates that mortality has dropped by almost 40% since 2010.

 

Source: 

https://www.who.int/gho/hiv/epidemic_status/deaths_text/en/

 

image26

Enzolytics currently holds a 49% Interest in Immunotech Laboratories BG-Europe. Immunotech BG-Europe has a license for the development and commercialization of Enzolytics Patented ITV-1 Technology. Immunotech BG-Europe , under the branded ImmunH , utilizing the technology has successfully completed Phase III clinical trials at the Specialized Hospital for Active Treatment of Infectious and Parasite Disease in Sofia, Bulgaria, specific for the treatment of HIV/AIDS.

 

ImmunoTech Laboratories BG-Europe has filed for a mass use permit, Phase IV, in Bulgaria. Enzolytics is seeking a Contract Manufacturing Organization (CMO) in the United States to produce the Immunotherapy Treatment to be used as the validation batch in coordination with the Bulgarian regulatory authority and Immunotech BG-Europe.

Additionally, ImmunoTech BG-Europe has informed Enzolytics that they will be seeking to register the ImmunH product as a ImmuneModulator, allowing use as an adjunct in additional applications to regulate or normalize the Immune System.

 

www.ImmunH.com

 

 

Enzolytics, Inc.

P.O. Box 5756 Frisco, TX

(972)-292-9414

 
*** ENZC 4-2020 A/S VERIFIED ONLY 1.5B ***

Unrestricted (FLOAT)
709,127,077
04/30/2020
https://www.tradingview.com/chart/ENZC/jDRnvjR4-ENZC-WEEKLY-SLING-SHOT-GETTING-STARTED/
 
ENZC
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#22985  Sticky Note ENZC biotech: why the insane over $7mil-traded-in-3-days? Q7 09/19/20 12:24:15 PM
#20470  Sticky Note ENZC HUGE BIOTECH MERGER NEWS!! BERKSHIRE AGENT 09/16/20 10:51:22 AM
#18484  Sticky Note everything points to commercialization and mass production, even moolamoola 07/17/20 01:06:06 PM
#25740   They do.... brezlin 09/27/20 09:40:05 PM
#25738   KNO* was on an extended steady upward trend . missile_systems 09/27/20 08:56:10 PM
#25737   Bloated SS - Pullback Obvious - Reload for BayTrader280 09/27/20 08:45:24 PM
#25736   BioClonetics INVITED by the National Science Foundation (NSF) MonstaGains 09/27/20 08:12:50 PM
#25735   Catchers mitt is out for the impatient flipper. Later southswell7 09/27/20 08:12:03 PM
#25734   Exactly. Just as The Gates Foundation does I southswell7 09/27/20 08:11:14 PM
#25733   Good chance Fauci knows who they are... brezlin 09/27/20 08:03:33 PM
#25732   I didnt predict a dollars Veloyt, I asked Bug2 09/27/20 07:55:21 PM
#25731   What is the float here please? ChowChowDog 09/27/20 07:32:47 PM
#25730   Bioclonetics uses monoclonal antibodies. This is HUGE for MonstaGains 09/27/20 07:31:50 PM
#25729   Dr. Fauci talks about monoclonal antibodies for COVID-19 MonstaGains 09/27/20 07:30:48 PM
#25728   twenty cents would be great before your $1 veloyt 09/27/20 07:26:09 PM
#25727   Minimum of $100 million before FDA approval and MonstaGains 09/27/20 07:25:18 PM
#25726   Question, whats a realistic stock price once it Bug2 09/27/20 07:11:17 PM
#25725   Thanks, it makes sense! Deportes 09/27/20 07:06:49 PM
#25724   Appropriate match for reverse merge into ENZC suny66 09/27/20 07:02:58 PM
#25723   Why does the privately owned Bioclonetics decided to Deportes 09/27/20 06:45:11 PM
#25722   Interesting bid DD behind that? Fibonacci pullback was about Shell Man 09/27/20 05:52:07 PM
#25721   Thanks I'm putting order just above that cause lazoom 09/27/20 04:38:23 PM
#25720   DD! Start it off with Diskmans post today: southswell7 09/27/20 04:38:02 PM
#25719   I'M NOT SURE HOW LONG I WILL HAVE -TEFFY-TRADER- 09/27/20 04:25:44 PM
#25718   Not that I know of. However I am Shell Man 09/27/20 03:44:16 PM
#25717   Thx has the comp been diluting shares? Or have Procera16 09/27/20 02:43:31 PM
#25716   IMO current very soon 8k 16April discussing it. Shell Man 09/27/20 02:34:33 PM
#25715   Is this going current anytime soon? Procera16 09/27/20 02:26:31 PM
#25714   Great point Shell:) Jisep 09/27/20 02:17:37 PM
#25713   The "long term" value here example: I bought Shell Man 09/27/20 02:11:02 PM
#25712   Great point Fd:) Jisep 09/27/20 02:10:48 PM
#25711   Designed to be traded? Fall in love with? Fdc4 09/27/20 02:06:23 PM
#25710   More news like that just creates more news gravytrain1 09/27/20 01:41:16 PM
#25709   Very nice article thank you... $ENZC strong! BluE33 09/27/20 01:35:03 PM
#25708   I like the prospects of this merger. Rekaewt 09/27/20 01:32:00 PM
#25707   Same goes.for those that sold. If you sold Rekaewt 09/27/20 01:30:20 PM
#25706   Next round of FOMO has started.. bottom was Rekaewt 09/27/20 01:27:03 PM
#25705   The best part is the headline section the Flicker1 09/27/20 01:26:44 PM
#25704   He’s a leftist! He doesn’t like people Jisep 09/27/20 01:01:45 PM
#25703   Gonna blow past a penny very soon - imo tripleDz 09/27/20 12:56:24 PM
#25702   Gonna get crazy I tell ya $ENZC$$$$. lazoom 09/27/20 12:49:05 PM
#25701   Hahaha, 52 million sold vs 22 Million bought, ALL-IN888 09/27/20 12:42:36 PM
#25700   ? Rockwall-based BioClonetics, a biotech startup working poncewaves 09/27/20 12:41:45 PM
#25699   https://dallasinnovates.com/icymi-whats-new-and-next-in-dallas-fort-worth-innovation/ = EXPOSURE southswell7 09/27/20 12:33:38 PM
#25698   I understand the Trader you are!! Your post southswell7 09/27/20 12:33:16 PM
#25697   Say no to drugs. papadedavid 09/27/20 12:32:56 PM
#25696   AGAIN JUST LIKE DAVID I WILL GIVE YOU 1plus1 09/27/20 12:31:45 PM
#25695   Yes, and ENZC has 1.2 billion on the papadedavid 09/27/20 12:31:27 PM
#25694   NEXT TIME I WILL ALERT YOU ANOTHER STOCK 1plus1 09/27/20 12:30:24 PM
#25693   1.6 Billion Float Good luck y'all!!! y'all are ALL-IN888 09/27/20 12:25:10 PM
#25692   RLFTF SECURITY DETAILS papadedavid 09/27/20 12:21:57 PM
#25691   Read post #25682 What dont you understand about that??? ALL-IN888 09/27/20 12:21:34 PM
#25690   Ignore this Poster folks. Wants as many cheapies southswell7 09/27/20 12:19:10 PM
PostSubject
Consent Preferences